FDA Clears Edesa's IND for EB06 Vitiligo Phase 2; U.S. Enrollment Starts Next Quarter

summarizeSummary

The FDA cleared Edesa's IND for a Phase 2 study of EB06 in vitiligo, letting the company add U.S. trial sites. Enrollment starts next quarter, with topline data not expected until Q4 2027.

check_boxKey Events · Product Development and Regulatory · EDSA

• FDA Clears EB06 Vitiligo IND

  The FDA cleared Edesa's IND application for a Phase 2 study of EB06 in vitiligo, enabling U.S. recruitment in addition to ongoing Canadian enrollment.

• Trial Design and Endpoint

  Double-blind, placebo-controlled study of up to 80 adults with moderate-to-severe nonsegmental vitiligo, randomized 1:1, dosed every two weeks through Week 22; primary endpoint is mean percent change in F-VASI at Week 28.

• Timeline: Data in Q4 2027

  First U.S. investigational sites are expected to begin enrolling next quarter, with topline data anticipated in the fourth quarter of 2027.

• Funded Against Going-Concern Warning

  The August 2026 10-Q disclosed a going concern warning that current resources won't fund operations through fiscal 2026; the $25 million offering priced 2026-08-20 at $5.50 per share plus warrants supports the expanded program.

auto_awesomeAnalysis · EDSA · Life Sciences

The FDA's acceptance of Edesa's IND for EB06 in vitiligo removes the biggest regulatory hurdle, allowing the Phase 2 study to enroll patients in the U.S. rather than only in Canada. That matters because the company warned in its August 10-Q that current resources won't fund operations through fiscal 2026, and a U.S.-enabled trial is the kind of progress that keeps partnering and financing options open. Timing is the catch: first U.S. sites enroll next quarter and topline data isn't expected until Q4 2027, so this is a de-risking step, not a near-term revenue event. The $25 million offering priced in August at $5.50 per share funds the work in the meantime.